BusinessProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b TrialBy Nasdaq OMXAug 29, 2017, 11:00 AM UTC
BusinessProQR Announces Results for the Second Quarter of 2017By Nasdaq OMXAug 16, 2017, 11:00 AM UTC
BusinessProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA TechnologyBy Nasdaq OMXJun 15, 2017, 11:05 AM UTC
BusinessProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science ConferenceBy Nasdaq OMXJun 13, 2017, 11:00 AM UTC
BusinessProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trialBy Nasdaq OMXJun 8, 2017, 1:04 PM UTC
